<DOC>
	<DOC>NCT00542555</DOC>
	<brief_summary>To study the efficacy and safety of naproxcinod vs. placebo and naproxen in the treatment of signs and symptoms of Osteoarthritis.</brief_summary>
	<brief_title>Analgesic Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee</brief_title>
	<detailed_description>This is a 13-week double-blind study followed by a 52-week, open-label, roll-over on active treatment study. These are randomized, parallel group, multicenter studies comparing efficacy and safety of naproxcinod, placebo and naproxen.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Naproxen-n-butyl nitrate</mesh_term>
	<criteria>Men and women (40 or older) with a diagnosis of primary OA of the knee Must be a current chronic user of NSAIDS or acetaminophen Must discontinue all analgesic therapy at screening Uncontrolled hypertension or diabetes Hepatic or renal impairment Current or expected use of anticoagulant A history of alcohol or drug abuse Candidates for imminent joint replacement Diagnosis of gastric or duodenal ulceration and/or history of significant gastroduodenal bleeding, within the last 6 months Current medical disease that could confound or interfere with the evaluation of efficacy Participation within 30 days prior to screening in another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>